EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer

Borui Li, Faliang Xing, Jingyi Wang, Xiaohong Wang, Chenjie Zhou, Guixiong Fan, Qifeng Zhuo, Shunrong Ji, Xianjun Yu, Xiaowu Xu, Yi Qin, Zheng Li

Cancer Letters · 2024-10 · 602 · 217197

DOI: 10.1016/j.canlet.2024.217197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-10. Verfasst von Borui Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, …. Hauptthemen laut MEDLINE: beta Catenin, Carcinoma, Pancreatic Ductal, Deoxycytidine, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Municipality Science and Technology Commission, Shanghai Municipal Natural Science Foundation, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is highly malignant and has a poor prognosis, without effective therapeutic targets in common gene mutations. Gemcitabine, a first-line chemotherapeutic for PDAC, confers

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta CateninCarcinoma, Pancreatic DuctalDeoxycytidineDrug Resistance, NeoplasmGemcitabineLow Density Lipoprotein Receptor-Related Protein-1Pancreatic NeoplasmsRibonucleoside Diphosphate ReductaseY-Box-Binding Protein 1AnimalsHumansMiceAntimetabolites, AntineoplasticCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticMice, NudeSignal TransductionTumor Suppressor ProteinsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Gemcitabine resistancePancreatic ductal adenocarcinomaRRM1Wnt/β-cateninYBX1

Substanzen

Antimetabolites, Antineoplasticbeta CateninCTNNB1 protein, humanDeoxycytidineGemcitabineLow Density Lipoprotein Receptor-Related Protein-1LRP1 protein, humanRibonucleoside Diphosphate ReductaseRRM1 protein, humanTumor Suppressor Proteins

Autor:innen und Institutionen

  • Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China; Shanghai Pancreatic Cancer…
  • Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, QLD 4067, Australia.
  • Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.

Förderung

  • Shanghai Municipality Science and Technology Commission
  • Shanghai Municipal Natural Science Foundation
  • Shanghai Municipal Health Commission
  • National Natural Science Foundation of China

Zitieren

APA

Li, B., Xing, F., Wang, J., Wang, X., Zhou, C., Fan, G., Zhuo, Q., Ji, S., Yu, X., Xu, X., Qin, Y., & Li, Z. (2024). YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Cancer Letters, 602, 217197. https://doi.org/10.1016/j.canlet.2024.217197

Vancouver

Li B, Xing F, Wang J, Wang X, Zhou C, Fan G, et al. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Cancer Letters. 2024;602:217197. doi:10.1016/j.canlet.2024.217197

BibTeX
@article{Li2024,
  author = {Li, Borui and Xing, Faliang and Wang, Jingyi and Wang, Xiaohong and Zhou, Chenjie and Fan, Guixiong and Zhuo, Qifeng and Ji, Shunrong and Yu, Xianjun and Xu, Xiaowu and Qin, Yi and Li, Zheng},
  title = {YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer},
  journal = {Cancer Letters},
  year = {2024},
  volume = {602},
  pages = {217197},
  doi = {10.1016/j.canlet.2024.217197}
}
Kostenlos starten →